Next, we tested for correlation of the methylation status of the candidate genes and PFS after treatment with CAPIRI therapy of metastatic CRC patients participating to the phase III CAIRO trial [12], which identified DCR1 as a candidate marker. This evidence concerns the gene TNFRSF10C and colorectal carcinoma.